FDA Accepts Supplemental NDA for DYNA-HEX 2 by XTTRIUM
The FDA has accepted a supplemental NDA for DYNA-HEX 2, which contains chlorhexidine gluconate.
Therapeutic Area
Therapeutic area intelligence for Antiseptic with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.